- CITATIONS: 2
|Application ||WB, IHC-P, E|
|Calculated MW||62769 Da|
|Other Names||Serine/threonine-protein kinase PINK1, mitochondrial, BRPK, PTEN-induced putative kinase protein 1, PINK1|
|Target/Specificity||Recombinant PINK1 protein was used to produced this monoclonal antibody.|
|Format||Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PINK1 Antibody (Ascites) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Protects against mitochondrial dysfunction during cellular stress by phosphorylating mitochondrial proteins. Involved in the clearance of damaged mitochondria via selective autophagy (mitophagy) by mediating activation and translocation of PARK2. Targets PARK2 to dysfunctional depolarized mitochondria through the phosphorylation of MFN2. Activates PARK2 in 2 steps: (1) by mediating phosphorylation at 'Ser-65' of PARK2 and (2) mediating phosphorylation of ubiquitin, converting PARK2 to its fully-active form (PubMed:24660806, PubMed:24751536, PubMed:24784582, PubMed:25527291).|
|Cellular Location||Mitochondrion outer membrane; Single-pass membrane protein Cytoplasm, cytosol. Note=Localizes mostly in mitochondrion and the 2 proteolytic processed fragments of 55 kDa and 48 kDa localize mainly in cytosol|
|Tissue Location||Highly expressed in heart, skeletal muscle and testis, and at lower levels in brain, placenta, liver, kidney, pancreas, prostate, ovary and small intestine. Present in the embryonic testis from an early stage of development|
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a serine/threonine protein kinase that localizes to mitochondria. It is thought to protect cells from stress-induced mitochondrial dysfunction. Mutations in this gene cause one form of autosomal recessive early-onset Parkinson disease.
Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. Maj MC, et al. Biochem Biophys Res Commun, 2010 Aug 27. PMID 20637729. Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson's disease. Keyser RJ, et al. Biochem Biophys Res Commun, 2010 Jul 16. PMID 20558144. Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Eggers C, et al. Neurology, 2010 Jun 1. PMID 20513816. Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Reetz K, et al. Neurobiol Dis, 2010 Sep. PMID 20483373. Clinical and demographic characteristics of PINK1 mutation carriers--a meta-analysis. Kasten M, et al. Mov Disord, 2010 May 15. PMID 20461815.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.